Thanks Surf. I am also lookin forward to results from Pfizers phase 2 in combination wth Tarceva against refractory NSCLC and their phase 1 with the immunotherapy CTLA4 for avanced Melanoma. To me it makes more sense to use a TLR9 agonist, which is an immune system primer, with a treatment that does not damage he immune system as many chemos do. They were sold down by the market as if they were dead in the water on cancer, which could not be further from the truth.
The Pharmas using their product are the bigest in the industry.
Pfizer, Sanofi-Aventis, GSK, Novartis, Merck. In applications from infectious diseases and cancer to alzheimers.
